IP Library Granted Patent US 7,745,400
Granted Patent B2
US 7,745,400 · App. 11/548,631 · Granted Jun 29, 2010

Prevention and treatment of ocular side effects with a cyclosporin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,745,400
App. No.
11/548,631
Granted
Jun 29, 2010
Kind
B2
Abstract

Presently described are methods of administration and associated treatment of one or more ocular conditions using cyclosporine, or an analog or derivative thereof. The ocular conditions can be a result of treatment using other therapeutic agents, such as chemotherapy agents, antiviral agents and immunomodulators.

Claims (11)

1. A method comprising administering cyclosporin A to an eye of a mammal in combination with administration of docetaxel to said mammal, wherein said method is effective in treating keratoconjunctivitis or conjunctivitis.

2. A method comprising administering cyclosporin A to an eye of a mammal in combination with administration of docetaxel or fluorouracil to the mammal, wherein the method is effective to treat abnormal lacrimation, keratitis, keratoconjunctivitis, or conjunctivitis.

3. The method of claim 2 , wherein the method is effective to treat abnormal lacrimation.

4. The method of claim 2 , wherein the method is effective to treat keratitis.

5. The method of claim 2 , wherein the method is effective to treat keratoconjunctivitis.

6. The method of claim 2 , wherein the method is effective to treat conjunctivitis.

7. A method comprising the step of administering cyclosporin A to an eye of a mammal undergoing treatment with docetaxel or fluorouracil, wherein the method is effective to treat abnormal lacrimation, keratitis, keratoconjunctivitis, or conjunctivitis.

8. The method of claim 7 , wherein the method is effective to treat abnormal lacrimation.

9. The method of claim 7 , wherein the method is effective to treat keratitis.

10. The method of claim 7 , wherein the method is effective to treat keratoconjunctivitis.

11. The method of claim 7 , wherein the method is effective to treat conjunctivitis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2017
From: ALLERGAN, INC.
To: SAINT REGIS MOHAWK TRIBE
Reel/Frame 043830/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2006
From: FEINERMAN, GREGG; BARTH, NEIL; SCHIFFMAN, RHETT M.; BARNETT, PAMELA S.
To: ALLERGAN, INC.
Reel/Frame 018415/0937 →